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Objective: The first generation of perieardial valves was withdrawn from the 
market because of a high rate of premature failure. With an original design, 
Carpentier-Edwards pericardial valves promised improved results. Meth- 
ods: One hundred fifty patients who underwent isolated mitral valve 
replacement, between July 1984 and December 1993, with Carpentier- 
Edwards pericardial bioprostheses in our institution were followed up. 
Patient mean age was 62.9 __ 11.9 years. Operative mortality was 3.3%. All 
but three patients were followed up for an average of 4.7 years after 
operation, and total follow-up was 710 patient-years. Results: At the time 
this article was written, over 80% of patients were in New York Heart 
Association class I or II. After 10 years, actuarial survival rate was 71% 
(confidence limit 61% to 81%). Valve-related complications included the 
following: six valve-related eaths (0.8% patient-year), five thromboembolic 
episodes (0.7% patient-year), three cases of endocarditis (0.4% patient- 
year), four reoperations (0.5% patient-year), and four structural valve 
failures with calcification and stenosis (0.5% patient-year). After 10 years, 
freedom from valve-related complications was 66% (confidence limit 46% to 
86%), from valve-related eath 94% (confidence limit 89% to 99%), from 
reoperation 90% (confidence limit 82% to 98%), and from valve failure 76% 
(confidence limit 62% to 90%). Conclusions: With a low rate of valve-related 
events at 10 years and a low rate of structural deterioration with no leaflet 
tear, this prosthesis is a reliable choice for patients over 60 years of age. 
(J Thorac Cardiovasc Surg 1997;113:492-8) 
T he first generation of pericardial valve has been abandoned by physicians for poor clinical results 
and a high rate of deterioration characterized by 
leaflet tear. With an original design, the Carpentier- 
Edwards pericardial bioprosthesis promised im- 
proved results. The intermediate follow-up showed 
a low rate of valve-related events and especially a 
low rate of deterioration with no leaflet tear, 1' 2 even 
in the mitral posit ion) This study reports our expe- 
rience over 10 years with 150 Carpentier-Edwards 
pericardiai mitrat valves (model 6900; Baxter 
Healthcare Corp., Santa Ana, Calif.) in 149 patients. 
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Material and methods 
Patients 
From July 1984 to December 1993, 150 Carpentier- 
Edwards pericardial bioprostheses were used in 149 con- 
secutive patients for isolated mitral valve replacement in
our hospital. Patients undergoing multiple valve replace- 
ment were excluded from this study, but there were no 
exclusion for other concomitant operations. There were 
71 men (47.3%) and 79 women (52.7%). Age ranged from 
22 to 82 years with a mean of 62.9 _+ 11.9 years; 46 patients 
were younger than 60 years old. 
Fifty-nine associated procedures included aortocoro- 
nary bypass in 13 patients, tricuspid annuloplasty in 28, 
and left atrium plication in 18. 
The main indications for valve replacement were rheu- 
matic fever in 55, dystrophic insufficiency in 41, prosthetic 
valve dysfunction in 15, failure of mitral valvuloplasty or 
commissurotomy in 13, endocarditis n 13, ischemic insuf- 
ficiency in 11, and valve thrombosis in 2. Clinical presen- 
tation was mitral stenosis in 38 patients, mitral insuffi- 
ciency in 91, and mixed disease in 21. Mean New York 
Heart Association (NYHA) clinical status was 2.7. Nine- 
teen percent of patients had a chronic atrial fibrillation. 
The preoperative status is summarized in Fig. 1. 
The patients underwent operation through a median 
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sternotomy with standard cardiopulmonary b pass, he- 
modilution, and general body hypothermia. Myocardial 
protection was obtained with crystalloid or blood car- 
dioplegic solution and topical cooling. A transseptal p- 
proach was used in patients with a small eft atrium and in 
cases of mitrotricuspid surgery. We preserved the poste- 
rior leaflet apparatus in every case, and since 1992 we 
have been trying to preserve the anterior leaflets appara- 
tus. We implanted 49, 66, 32, and 3 prostheses in 27, 29, 
30, and 33 mm sizes, respectively. 
Postoperative anticoagulant protocol included heparin 
for 2 days, followed by 1 month of calcium heparin 
(activated partial thromboplastin time > 1.5N) or aceno- 
coumarol (international normalized ratio 1.5:2) (Giba, 
Geigy, France). After 1 month, the anticoagulation treat- 
ment was discontinued except in patients in atrial fibril- 
lation; the treatment was sometimes modified according 
to the cardiologist's decision. 
Patients were followed up every other year at the same 
date and with the same procedure. The 10-year follow-up 
information was obtained during a 3-month interval 
through questionnaire and telephone contact with cardi- 
ologist, family physician, and patient. All but three pa- 
tients were followed up for an average of 4.7 years after 
their operation, and total follow-up was 710 patient-years 
(2% lost to follow-up). 
More than 95% of patients underwent an echocardio- 
graphic study at the time of follow-up; among them 30 
patients underwent echocardiographic Doppler studies at 
our institution. They were performed by the same physi- 
cian with the same procedure. 
All data were entered in an |BM computer and ana- 
lyzed with Sedistat software (Sedia SA, Paris, France). 
Standard actuarial and linearized statistical techniques 
were used to describe survival and incidence of valve- 
related complications. Only the first event for each patient 
during the study was considered in the actuarial analysis, 
whereas all events for each patient were considered in 
linearized rates. Continuous data are presented as 
mean -+ standard eviation, and actuarial probability and 
linearized rates are presented as mean and 95% confi- 
dence limits (CL) of the mean. The time interval used for 
actuarial analysis is in years. Linearized rates are numbers 
of events per person-year of follow-up. 
The guidelines for reporting mortality and morbidity 
after cardiac valvular operation have been observed in the 
preparation of this article. 4 
Results 
Patient survival 
Five patients died within 30 days of the operative 
period, for a mortality of 3.3%. The major cause 
of early death was cardiac failure in three pa- 
tients. One patient died of pulmonary embolism, 
and another patient died of left ventricular up- 
ture. There were no deaths for patients in NYHA 
class I or II. 
There were 27 late deaths. The cause of death was 
cardiac-related in six patients (22%), valve-related 
in six (22%), and noncardiac in 15 (56%). The 
actuarial survival rate including operative mortality 
was 71% (CL 61% to 81%) after 10 years (Fig. 2). 
At the time this article was written, over 80% of 
the 117 patients followed up were in NYHA class I 
or II (Fig. 1), with 56 receiving anticoagulation 
treatment. Of these, 32 were in atrial fibrillation, 16 
had a pacemaker, and eight were in sinus rhythm. 
Good quality of life (no noise and no anticoagula- 
tion) was especially noted in younger patients. 
Valve-related complications. Six patients died of 
valve-related causes (two of endocarditis, one of 
thromboembolic complication, one of anticoagu- 
lant-related hemorrhage, and two of sudden death). 
The actuarial rate of freedom from valve-related 
death was 94% (CL 89% to 99%) at 10 years. No 
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Fig. 2. Patients' actuarial survival. 
postmortem examination was available for the sud- 
den death. 
Thromboembolism. Five patients had a thrombo- 
embolic accident for an actuarial rate of 95% (CL 
90% to 100%) of patients free of thromboembolism 
at 10 years. The five events were neurologic: one 
death, one permanent neurologic deficit, and three 
without sequelae. Three patients were in sinus 
rhythm, two were in atrial fibrillation, and two had 
anticoagulation treatment (one in sinus rhythm, one 
in atrial fibrillation). Linearized rate was 0.7% pa- 
tient-years. No thrombosis of the bioprosthesis was 
observed. 
Anticoagulant-related hemorrhage. There were 
nine cases of hemorrhagic omplications meeting 
the definition of the guidelines, with one death. Of 
these, three were in sinus rhythm and had no 
indication for anticoagulation. Linearized rate was 
1.2% patient-year, and 10-year freedom from anti- 
coagulant hemorrhage was 84% (CL 70% to 98%). 
Endocarditis was reported in three patients, with 
one in the first 3 months and two in the first year. 
Two patients died without reoperation, but the 
diagnosis was not made in our institution, and one 
had successful medical treatment without recur- 
rence. The linearized rate of endocarditis was 0.4% 
patient-years with an actuarial rate of 97% (CL 94% 
to 100%) of patients being free of endocarditis at 10 
years. No hemolysis was noted in the patients who 
were followed up. 
Four patients required reoperation for an actuar- 
ial rate of 90% (CL 82% to 98%) of patients free of 
reoperation at 10 years and a linearized rate of 0.5% 
patient-years. Causes of reoperation were perivalvu- 
lar leak in one and structural failure in three. We 
used another pericardial bioprosthesis in one case 
and a mechanical prosthesis in three. No mortality 
was noted for the patients with reoperations, all of 
which were elective. 
There were only four patients with structural 
deterioration of the valve for an actuarial rate of 
76% (CL 52% to 100%) of patients free of struc- 
tural valve failure at 10 years and a linearized rate of 
0.5% patient-years (Fig. 3). The valve was consid- 
ered as deteriorated when a mitral insufficiency of 
grade III or IV was observed or when the mean 
transvalvular gradient was above 8 mm Hg. Despite 
the short coaptation area of the leaflet, no major 
central insufficiency was noted in the patients who 
were being followed up. Except in patients with 
structural failure, we observed no major structural 
change. Four patients underwent reoperation, one 
after the end of the study. The structural change was 
stenosis without regurgitation caused by valve calci- 
fication in all cases. The explanted valve showed 
diffuse micromineralization f the three leaflets. 
It is notable that no leaflet tear was observed. 
Patient ages were 23, 27, 40, and 41 years, and the 
delay for calcification was 9, 8.5, 5.5, and 5 years, 
respectively. No major structural change was 
noted in the other patients who were followed up, 
but echocardiographic studies were not per- 
formed in all patients. 
Age 
Forty-six patients were under 60 years of age. In 
this group, with a mean follow-up of 5.6 years and 
total follow-up of 258 patient-years, we observed 
two valve-related eaths and nine valve-related 
events (Table I). Actuarial survival was 81% (CL 
69% to 93%) at 10 years. Actuarial freedom from 
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Fig. 3. Actuarial rates for freedom from structural deterioration. 
Table I. Valve-related complications 
All patients Patients <60 yr Patients >60 yr 
Valve-related death 
Thromboembolism 
Endocarditis 
Structural failure 
Reoperations 
Anticoagulation-related h morrhage 
All complications 
0.8% (89%-99%) 
0.7% (90%-100%) 
0.4% (94%-100%) 
0.5% (52%-100%) 
0.5% (82%-98%) 
1.2% (70%-98%) 
3.1% (46%-86%) 
0.7% (90%-100%) 
0.3% (94%-100%) 
o (loo%) 
1.5% (12%-82%) 
1.1% (58%-98%) 
1.5% (52%-100%) 
4.2% (1%-71%) 
o.8% (90%-98%) 
0.9% (90%-100%) 
0.6% (92%-100%) 
o (loo%) 
0.2% (96%-100%) 
1.1% (84%-100%) 
2.8% (70%-90%) 
Valves are Iinearized rate and actuarial freedom (95% CL). 
valve-related death was 95% (CL 90% to 100%), 
from endocarditis 100%, from thromboembolism 
97% (CL 94% to 100%), from deterioration 47% 
(CL 12% to, 82%), and from reoperation 78% (CL 
58% to 98%). Actuarial freedom of all valve-related 
complications was 36% (CL 1% to 71%). 
One hundred four patients were older than 60 years. 
In this group, with a mean follow-up of 4.3 years and a 
total follow-up of 452 patient-years, we observed four 
valve-related deaths and nine valve-related events (Ta- 
ble I). Actuarial survival was 65% (CL 52% to 78%) at 
10 years. Actuarial freedom from valve-related death 
was 94% (CL 90% to 98%), from endocarditis 96% 
(CL 92% to 100%), from thromboembolism 95% (CL 
90% to 100%), from deterioration 100%, and from 
reoperation 98% (CL 96% to 100%). Actuarial free- 
dom of all valve-related mortality and morbidity was 
8O% (CL 70% to 90%). 
Hemodynamics 
Among the 30 patients assessed by echocardiog- 
raphy at the time of follow-up in our institution, 14 
had a mitral valve replacement with a 27 mm 
bioprosthesis, eight with a 29 mm, six with a 31 mm, 
and two with a 33 mm. Hemodynamics data are 
shown in Table II. 
Discussion 
The procedure of choice for mitral valve disease is 
mitral repairS; it represents about 50% of our mitral 
surgery activity. The use of mitral homografts 6 in- 
creases the indications for repair, but the problem of 
technical procedure and procurement introduces a 
major limitation. For other patients, the ideal valve 
is not yet available and surgeons need to choose 
between mechanical prostheses with the risk of 
anticoagulant-related hemorrhage and biologic 
valves with the risk of deterioration and reopera- 
tion. 7 The use of biologic valves in the mitral 
position is controversial. The incidence of structural 
deterioration and the need for reoperation appear 
higher than in the aortic position, and many studies 
conclude with a clinical use limitation in patients 
over 70 years of age. 
Pericardial bioprostheses have been clinically 
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Table II. Hemodynamic data 
Valve size Mean gq~adient Effective orifice 
(ram) n (ram Hg) (cm e) 
27 14 4.1 2.6 
29 8 3.0 2.7 
31 6 3.0 2.6 
33 2 3.0 3.1 
used in human beings since 1970. The first genera- 
tion of this type of valve has been withdrawn from 
the market because of its poor clinical results. 8'9 
The mode of deterioration was largely documented 
and was not due to pericardium failure but to design 
failure10, 11 or tissue preparation failure. 12 
The Carpentier-Edwards pericardial valve was 
designed with an original eaflet clamping technique 
which eliminates the retention suture and also abra- 
sion risk. Pericardium is carefully procured and 
treated with glutaraldehyde. With these characteris- 
tics, this pericardial bioprosthesis showed satisfac- 
tory intermediate r sults 13' 14 in both positions, re- 
establishing pericardium as a good valve substitute. 
These results, especially in the mitral position, 
promise an interesting long-term follow-up. 
Few reports are available with this type of peri- 
cardial valve, except for one publication with a long 
follow-up. 15 The aortic and mitral Edwards pericar- 
dial valves were first used in Europe, and the aortic 
prosthesis received Food and Drug Administration 
(FDA) approval in 1991. The present models of the 
Carpentier-Edwards pericardial bioprostheses sold 
outside the United States are the model 2900 (aor- 
tic) and the model 6900 (mitral). The difference in 
these models as compared with the aortic model 
2700 sold in the United States lies in the configura- 
tion of the valves' sewing rings. Considering that 
these changes to the sewing ring were not incorpo- 
rated until after the initiation of the model 2700 
U.S. clinical trials, Edwards CVS division of Baxter 
Healtcare Corporation made the business decision 
to continue its original study with the model 2700 
rather than start over with a new submission to the 
FDA on the models 2900 and 6900. The company is 
currently in the process of developing a mitral 
version for future sale within the United States. 
We report here one of the largest studies with this 
prosthesis but with a low number of patients at risk 
at 10 years and a mean 4.7-year follow-up. 
We have been using these pericardial valves in the 
mitral position since 1984 in a total of 149 patients, 
who represent more than half of all valve replace- 
ments during the same period. It is the only biopros- 
thesis used for mitral valve replacement in our 
institution. We used these pericardial valves in 
patients over 60 years of age and in case of contra- 
indications to anticoagulant therapy. We also used it 
in patients with poor clinical status and in young 
patients who wish to avoid anticoagulant treatment 
after informed consent. 
In this study, overall rate of survival was 71% and 
the rate and cause of death were similar to those in 
other reports on mitral valve replacement. 16'17 
There were six valve related-deaths, among them 
two sudden deaths. No postmortem examination 
was available when these deaths occurred in other 
institutions or at home. Despite this fact the actu- 
arial freedom of valve-related death is comparable 
with other studies. 
The morbidity with this prosthesis is low. The 
most important complication was embolism in five 
patients but without thrombosis of the prosthesis. 
This low rate of embolism occurred in the absence 
of anticoagulation i patients in sinus rhythm or 
with a low international normalized ratio (1.5 < 
INR < 2) in patients in atrial fibrillation. Freedom 
of embolism at 10 years is 95%. This rate appears 
lower than the rate obtained in patients with me- 
chanical prostheses who were much younger in 
many studies, is
Despite the large number of patients with antico- 
agulation treatment because of atrial fibrillation 
only nine accidents and one death caused by anti- 
coagulant-related hemorrhage were noted. The rate 
of hemorrhage (1.2% patient-year) is lower than 
those published with mechanical prostheses, l<19 
The greater isk with mechanical prosthesis is re- 
lated to the higher ecommended INR (INR > 2.5). 
We observed only four cases of structural deteri- 
oration. Tissue deterioration was always the same: 
leaflet calcification leading to valve stenosis. Ex- 
planted valves showed intrinsic calcification of the 
three leaflets. No leaflet ears were observed in this 
study. 
Comparison of the long-term results with other 
valves is difficult because many factors vary between 
cardiac surgical teams. Our results at 10 years in 
particular are better than those obtained with earlier 
pericardial bioprostheses. There is a significant dif- 
ference in the structural deterioration rate between 
the Carpentier-Edwards and the first generation of 
pericardial valves (Ionescu-Shiley, Shiley, Inc, Calif.; 
Hancock, Medtronic, Cardiopulmonary Division, 
Anaheim, Calif.). The reported rates for the Io- 
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nescu-Shiley 2° are close to 40% at 10 years, whereas 
it is approximately 30% for the Hancock pericardial 
bioprosthesis 21 at 7 years. 
The behavior of these pericardial valves compares 
well with those published for standard porcine 
valves.aa, 23 The last generation of porcine valves 
showed promising results, 24' 2s but no comparison is 
available between these porcine valves and the latest 
generation of pericardial valves. This type of study is 
needed especially for patients younger than 70 years 
of age. 
A comparison between mechanical and biologic 
valves was made by Bloomfield 26 and Hammermeis- 
ter. 27 This study was carried out on the first gener- 
ation of pericardial valves and porcine valves. The 
better results obtained with the latest generation of 
pericardial valves will certainly change the results of 
the comparison. However, Cohn and colleagues 2s 
believe long-term survival after mitral valve replace- 
ment is primarily related to patient variables. 
As already reported, 29 the influence of age is 
again clearly shown in this study. No patient over 50 
years of age had structural deterioration at a mean 
follow-up period of 4.7 years. This pericardial valve 
appears to be a reliable choice for patients over 50 
years and is a prosthesis of choice in patients over 60 
years even in case of atrial fibrillation. We think that 
selection of patients remains indispensable even 
with the latest generation of biologic valves and that 
a more durable bioprosthesis in the mitral position 
for young patients is needed. 
Conclusion 
With a low rate of valve-related events at l0 years 
and especially a low incidence of structural failure, 
this prosthesis reestablishes the pericardium as a 
valve substitute in the mitral position. It is a reliable 
choice in patients over 60 years. However, because 
of the history of bioprostheses and our relatively 
short mean follow-up of 4.7 years, further studies 
and longer follow-up are necessary to provide de- 
finitive conclusions. 
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